Boehringer Ingelheim has reported positive topline results from the phase III SYNCHRONIZE‑1 trial, showing that its investigational dual glucagon/GLP‑1 agonist survodutide achieved sustained and ...

UK spin‑out speeds up development and reduces animal testing A UK biotech company has launched what it describes as a world‑first platform of lab‑grown human muscle designed to give drug developers ...

BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform ...

David Apelian, CEO of Theolytics, said: “We are proud to announce the dosing of the first patient in this important study.” ...

The UK’s Medicines & Healthcare Products Regulatory Agency has granted marketing authorisation to Enflonsia (clesrovimab), ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...

Kahimmune Therapeutics has signed a scientific collaboration agreement with Gustave Roussy to support the selection and development of its first shared mRNA companion neoantigen therapy candidate, KAH ...